{"id":29028,"date":"2020-02-10T12:51:14","date_gmt":"2020-02-10T10:51:14","guid":{"rendered":"https:\/\/mssociety.org.il\/?p=29028"},"modified":"2021-01-30T12:10:46","modified_gmt":"2021-01-30T10:10:46","slug":"hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study","status":"publish","type":"post","link":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/","title":{"rendered":"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study"},"content":{"rendered":"<p style=\"direction: ltr; text-align: justify;\">Researchers from Florence, Italy report on a small, open-label study involving 26 people with moderate to severe secondary progressive MS who underwent HSCT (Hematopoietic Stem Cell Transplantation). Most showed signs of clinical or MRI inflammatory activity in the year prior to the procedure. Five years after the procedure, 42% of participants were stable with no further progression of disability that was reduced to 30% 10 years after transplant. No relapses or inflammatory activity occurred on MRI scans after treatment. These results suggest that HSCT might be appropriate in a subgroup of people with SPMS that have significant inflammatory activity as measured by MRI. Further study in larger numbers are needed to understand who among those with secondary progressive MS might benefit from HSCT.<\/p>\n<ul>\n<li style=\"direction: ltr; text-align: justify;\"><span style=\"font-size: 14pt; color: #ff6600;\"><strong>HSCT<\/strong><\/span> attempts to \u201creboot\u201d the immune system, which is involved in damaging the brain and spinal cord in MS. In HSCT for MS, hematopoietic (blood cell-producing) stem cells, which are derived from a person\u2019s own (scientifically referred to as \u201cautologous\u201d) bone marrow, are collected and stored, prior to depleting much of the immune system using chemotherapy drugs. Then the stored hematopoietic stem cells are reintroduced to the body and over time reconstitute the immune system.<\/li>\n<li style=\"direction: ltr; text-align: justify;\">The primary outcome of this study was absence of further disease progression, which was achieved in 42% of participants at 5 years, and 30% at 10 years. In another 10 participants, disease progressed once, and then stabilized. The other 6 experienced disease progression to severe disability.<\/li>\n<li style=\"direction: ltr; text-align: justify;\">No deaths or life-threatening complications occurred. Two people developed autoimmune thyroid inflammation, and one person who had previously been treated with cell-inhibiting therapies developed myelodysplastic syndrome (a type of cancer). The most common adverse events were fever, gastrointestinal effects, and viruses\/infections.<\/li>\n<li style=\"direction: ltr; text-align: justify;\">In HSCT, conditioning (immunosuppressive) regimes can vary from low to medium to high intensity. This study used an intermediate-intensity regimen known as BEAM. A new HSCT trial using the BEAM regimen is recruiting participants with relapsing-remitting MS.<\/li>\n<\/ul>\n<p style=\"direction: ltr; text-align: justify;\">\u201cImpact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis\u201d was published by Drs. Alice Mariottini, Luca Massacesi, and colleagues at Careggi University Hospital, Florence, Italy, in the MS Journal.<\/p>\n<h3 style=\"direction: ltr; text-align: justify;\">About Multiple Sclerosis<\/h3>\n<p style=\"direction: ltr; text-align: justify;\">Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS.<\/p>\n<p style=\"direction: ltr; text-align: justify;\">Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers from Florence, Italy report on a small, open-label study involving 26 people with moderate to severe secondary progressive MS who underwent HSCT (Hematopoietic Stem Cell Transplantation). Most showed signs [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[429,384],"tags":[],"class_list":["post-29028","post","type-post","status-publish","format-standard","hentry","category-innovations-in-research-israel-and-around-the-world","category-articles"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study - The Israel Multiple Sclerosis Society<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study - The Israel Multiple Sclerosis Society\" \/>\n<meta property=\"og:description\" content=\"Researchers from Florence, Italy report on a small, open-label study involving 26 people with moderate to severe secondary progressive MS who underwent HSCT (Hematopoietic Stem Cell Transplantation). Most showed signs [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/\" \/>\n<meta property=\"og:site_name\" content=\"The Israel Multiple Sclerosis Society\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/agudaims\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-10T10:51:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-01-30T10:10:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"176\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb\"},\"headline\":\"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study\",\"datePublished\":\"2020-02-10T10:51:14+00:00\",\"dateModified\":\"2021-01-30T10:10:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/\"},\"wordCount\":476,\"publisher\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#organization\"},\"articleSection\":[\"Innovations in research- Israel and around the world\",\"Articles\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/\",\"url\":\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/\",\"name\":\"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study - The Israel Multiple Sclerosis Society\",\"isPartOf\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#website\"},\"datePublished\":\"2020-02-10T10:51:14+00:00\",\"dateModified\":\"2021-01-30T10:10:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u05e8\u05d0\u05e9\u05d9\",\"item\":\"https:\/\/mssociety.org.il\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research\",\"item\":\"https:\/\/mssociety.org.il\/en\/category\/research\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Innovations in research- Israel and around the world\",\"item\":\"https:\/\/mssociety.org.il\/en\/category\/research\/innovations-in-research-israel-and-around-the-world\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#website\",\"url\":\"https:\/\/mssociety.org.il\/en\/\",\"name\":\"The Israel Multiple Sclerosis Society\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mssociety.org.il\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#organization\",\"name\":\"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4\",\"url\":\"https:\/\/mssociety.org.il\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png\",\"contentUrl\":\"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png\",\"width\":600,\"height\":176,\"caption\":\"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4\"},\"image\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/agudaims\",\"https:\/\/www.youtube.com\/channel\/UCCfPf2JEIWquD7cPkWzK9ow\/videos\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g\",\"caption\":\"admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study - The Israel Multiple Sclerosis Society","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/","og_locale":"en_US","og_type":"article","og_title":"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study - The Israel Multiple Sclerosis Society","og_description":"Researchers from Florence, Italy report on a small, open-label study involving 26 people with moderate to severe secondary progressive MS who underwent HSCT (Hematopoietic Stem Cell Transplantation). Most showed signs [&hellip;]","og_url":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/","og_site_name":"The Israel Multiple Sclerosis Society","article_publisher":"https:\/\/www.facebook.com\/agudaims","article_published_time":"2020-02-10T10:51:14+00:00","article_modified_time":"2021-01-30T10:10:46+00:00","og_image":[{"width":600,"height":176,"url":"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/#article","isPartOf":{"@id":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/"},"author":{"name":"admin","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb"},"headline":"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study","datePublished":"2020-02-10T10:51:14+00:00","dateModified":"2021-01-30T10:10:46+00:00","mainEntityOfPage":{"@id":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/"},"wordCount":476,"publisher":{"@id":"https:\/\/mssociety.org.il\/en\/#organization"},"articleSection":["Innovations in research- Israel and around the world","Articles"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/","url":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/","name":"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study - The Israel Multiple Sclerosis Society","isPartOf":{"@id":"https:\/\/mssociety.org.il\/en\/#website"},"datePublished":"2020-02-10T10:51:14+00:00","dateModified":"2021-01-30T10:10:46+00:00","breadcrumb":{"@id":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mssociety.org.il\/en\/hsct-shows-benefits-in-some-people-with-secondary-progressive-ms-in-small-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u05e8\u05d0\u05e9\u05d9","item":"https:\/\/mssociety.org.il\/en\/"},{"@type":"ListItem","position":2,"name":"Research","item":"https:\/\/mssociety.org.il\/en\/category\/research\/"},{"@type":"ListItem","position":3,"name":"Innovations in research- Israel and around the world","item":"https:\/\/mssociety.org.il\/en\/category\/research\/innovations-in-research-israel-and-around-the-world\/"},{"@type":"ListItem","position":4,"name":"HSCT Shows Benefits in Some People with Secondary Progressive MS in Small Study"}]},{"@type":"WebSite","@id":"https:\/\/mssociety.org.il\/en\/#website","url":"https:\/\/mssociety.org.il\/en\/","name":"The Israel Multiple Sclerosis Society","description":"","publisher":{"@id":"https:\/\/mssociety.org.il\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mssociety.org.il\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mssociety.org.il\/en\/#organization","name":"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4","url":"https:\/\/mssociety.org.il\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png","contentUrl":"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png","width":600,"height":176,"caption":"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4"},"image":{"@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/agudaims","https:\/\/www.youtube.com\/channel\/UCCfPf2JEIWquD7cPkWzK9ow\/videos"]},{"@type":"Person","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g","caption":"admin"}}]}},"_links":{"self":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/posts\/29028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/comments?post=29028"}],"version-history":[{"count":0,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/posts\/29028\/revisions"}],"wp:attachment":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/media?parent=29028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/categories?post=29028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/tags?post=29028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}